UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Week of September 28–October 2, 2026. A more selective non-biotech watchlist: three relative-strength candidates, two event-led cases that still need confirmation, and a candid audit of the previous technical selection. The question is where company evidence and market behaviour agree—not which stock can be promised a green week.
Research published September 25, 2026, before the U.S. regular session. Price cutoff: September 24 close. Forward window: September 28–October 2. Friday September 25 is not included in the performance audit or charts. Premarket prices are not substituted for completed daily candles.
IWM closed at $281.66, below SMA20 $289.50 and SMA50 $294.28. MDY closed at $663.74, also below both averages. SPY at $767.18 remained above its corresponding averages. From August 24 to September 24, price returns were IWM −5.47%, MDY −4.42% and SPY +0.49%. This is weak small/mid-cap participation, not a broad small-cap tailwind. These ETFs are market-segment proxies, not index total-return series.
The Federal Reserve raised its target range by 25 basis points to 3.75–4.00% on September 16. The coming PCE inflation report, manufacturing survey and employment report can therefore overwhelm a company-specific setup. A softer inflation reading could help rate-sensitive shares; firmer inflation could pressure valuations. Weak employment can also damage demand expectations, so a weak report is not automatically bullish. Federal Reserve, September 16.
Editorial conclusion: SPNT, SPSC and AVT combine relative strength with identifiable operating businesses and rising intermediate averages. Their weaknesses are different: SPNT has not held its intraday breakout, SPSC lacks strong volume confirmation, and AVT is extended. BB and EFOR have fresh company developments but weaker confirmation; they are separated from the three technical candidates. No numerical probability of a rise is claimed.
The primary screen returned 193 liquid small/mid-cap names meeting its snapshot filters; 49 healthcare names were outside this non-biotech remit, leaving 144 discovery candidates. Deeper daily-price work covered 37 individual equities and three benchmark ETFs, including the complete previous 17-name edition, company-event candidates and alternatives. Five cases are developed below. This is a documented editorial funnel, not an exhaustive market ranking or a validated forecasting model.
Three technical candidates · Two conditional events · Week-ahead calendar · Previous-edition audit · Why other names did not qualify
| Ticker | Company | Sep 24 close · USD | Sep 18–24 price change | vs IWM · percentage points | Research status | Why it is on the list |
|---|---|---|---|---|---|---|
| $SPNT | SiriusPoint | 25.80 | +4.24% | +5.10 pp | Technical candidate | Profitable underwriting, positive relative strength and higher volume; the latest breakout attempt did not hold. |
| $SPSC | SPS Commerce | 82.69 | +3.70% | +4.56 pp | Technical candidate | Above rising intermediate trend, near SMA20; MAX launch is real, but incremental AI revenue is unproven. |
| $AVT | Avnet | 100.91 | +4.98% | +5.84 pp | Technical candidate · extension risk | Strong relative performance and operating growth; stretched chart, working-capital use and leverage limit the case. |
| $BB | BlackBerry | 8.73 | +9.26% | +10.12 pp | Conditional event case | September 24 results and September 22 design win; above-normal volume, but the 50-session average still declines. |
| $EFOR | Everforth | 32.43 | -1.01% | -0.15 pp | Conditional event case | September 24 SUNet extension and price near SMA20; a contract ceiling is not funded revenue. |
The green or red change describes the period before this edition, not the expected result next week. Historical relative strength is a filter, not evidence that next week must be positive. The fixed forward comparison for this edition is September 25 close to October 2 close, against IWM over the same interval. Those closes are not yet available. All five names must remain in that audit, with the three technical candidates and two conditional cases reported separately; a failed or unconfirmed case is not removed retrospectively.
Technical candidate: Relative strength in specialty insurance, with a failed intraday breakout to resolve
September 24 close $25.80 · SMA20 $24.61 · SMA50 $24.27 · volume/prior20 2.40× (IBKR series)
Business evidence and why now. SiriusPoint provides a different source of operating risk from miners, tankers and semiconductor names. Its July 29 second-quarter release reported $69 million of common net income and 6% growth in core gross premiums. The core combined ratio was 91.4%, below the 100% underwriting break-even reference, although weaker than 89.5% a year earlier. The first-half ratio improved to 90.1% from 92.4%. These are profitable insurance operations, but the latest quarter was not an uninterrupted acceleration. Common-share repurchases reached $95 million by July 28; that is historical capital return, not guaranteed buying next week. No material company event has been verified for September 28–October 2: the weekly thesis is technical persistence supported by the existing business.
What the price confirms—and what it does not. The September 24 close of $25.80 was above SMA20 $24.61 and SMA50 $24.27. The 50-session average had risen only 0.32% over ten sessions, so the intermediate trend is positive but shallow. The stock gained 4.24% from September 18 while IWM fell 0.86%. Participation was above its prior-20-session norm in both checked feeds: 2.40× in IBKR and 1.65× in Finviz. However, the session traded up to $26.50 and then closed below the earlier $26.16 high. That is a rejected intraday advance, not a completed breakout.
What would strengthen the case. A subsequent close above the $26.16–26.50 observed resistance area, followed by acceptance rather than an immediate reversal, would strengthen the continuation case. Holding the $24.61–24.27 moving-average area while relative strength stays positive would preserve the less aggressive consolidation interpretation. The case does not depend on a forecast that yields must fall, or on an unverified analyst price target.
What would weaken or invalidate the case. Repeated closes below the moving-average area would weaken the technical advantage; a break of the observed $23.93 ten-session low would invalidate this particular consolidation. Catastrophe losses, reserve deterioration, weaker underwriting pricing and investment-portfolio losses can override the chart. Q2 core underwriting income declined to $55 million from $67.6 million, so the premium-growth headline must not be mistaken for rising profitability in every period. Market strength has not established that the stock is undervalued.
July 29 results · Q2 Form 10-Q
Observed reference range: prior-20-session high $26.16; latest 10-session low $23.93. ATR14 $0.63 (2.44% of the close). These describe the chart, not an entry, stop order or price objective. No company event on September 28–October 2 is assumed unless explicitly listed.
Blue: SMA20. Purple: SMA50 (starts only when 50 observations are available). Candles: green close ≥ open; red close < open. Lower bars: IBKR reported volume, scaled to the chart maximum. No future prices or projected returns. On small screens, scroll the chart horizontally.
Source: IBKR daily RTH TRADES; Merlintrader calculations. Prices through September 24, 2026.
Technical candidate: A relatively unextended recovery, supported by recurring revenue but awaiting stronger demand for the shares
September 24 close $82.69 · SMA20 $81.88 · SMA50 $76.19 · volume/prior20 0.61× (IBKR series)
Business evidence and why now. SPS Commerce connects retailers and suppliers through supply-chain software. On September 15 it announced general availability of MAX, initially for Fulfillment and Visibility Management. The commercial product milestone is verified; the company did not quantify incremental MAX revenue. July 30 Q2 results reported revenue of $197.8 million, up 6%, and adjusted EBITDA of $66.6 million, up 19%. Recurring revenue also grew 6%. The September product release supplies current context, while the actual one-week case remains a technical consolidation—not an assumed results announcement or an AI revenue forecast.
What the price confirms—and what it does not. At $82.69 the stock was just 0.99% above SMA20 $81.88, while SMA50 stood at $76.19 and had risen 5.71% over ten sessions. The September 18–24 gain of 3.70% exceeded IWM by 4.56 percentage points. That gives the case a measurable trend advantage without the large short-term extension of AVT or BB. The important weakness is participation: September 24 IBKR volume was only 0.61× its previous 20-session average. Price stabilization is visible; a strong new accumulation signal is not.
What would strengthen the case. Repeated closes above the short average, followed by a recovery toward the observed $89.44 twenty-session high with better participation, would improve the evidence. A break above that prior high would be a new observation to verify, not an outcome presumed by the chart. Further disclosures of customer adoption and monetization would matter more than repeating the general AI theme. Neither management nor this analysis supplies a dated revenue catalyst for the coming week.
What would weaken or invalidate the case. A loss of $81.88 would weaken the short-term consolidation; the observed $77.06 ten-session low is the more important failure reference for this setup. Q2 GAAP EPS fell to $0.19 from $0.52, partly reflecting a $23.45 million loss on the sale of the 3P Revenue Recovery business. The disposal removes about $10.5 million from expected second-half revenue; management expected an approximately neutral adjusted-EBITDA effect. Cash was $173.17 million at June 30. Buybacks do not eliminate dilution: the 10-Q also discloses outstanding equity awards and options. Slow growth or weak AI monetization could limit the re-rating even if the product works.
September 15 MAX launch · July 30 Q2 results · Q2 Form 10-Q
Observed reference range: prior-20-session high $89.44; latest 10-session low $77.06. ATR14 $3.20 (3.87% of the close). These describe the chart, not an entry, stop order or price objective. No company event on September 28–October 2 is assumed unless explicitly listed.
Blue: SMA20. Purple: SMA50 (starts only when 50 observations are available). Candles: green close ≥ open; red close < open. Lower bars: IBKR reported volume, scaled to the chart maximum. No future prices or projected returns. On small screens, scroll the chart horizontally.
Source: IBKR daily RTH TRADES; Merlintrader calculations. Prices through September 24, 2026.
Technical candidate · extension risk: An electronics-distribution upcycle with strong price leadership and a demanding cash-flow test
September 24 close $100.91 · SMA20 $93.57 · SMA50 $91.89 · volume/prior20 1.65× (IBKR series)
Business evidence and why now. Avnet’s August 5 release reported fiscal Q4 sales of $8.295 billion, up 47.7% year over year and 16.5% sequentially, with adjusted EPS of $2.28 versus $0.81. Management guided the next quarter to $9.0–9.3 billion of revenue and $2.80–2.90 adjusted EPS. This gives the semiconductor and components narrative a specific link to distribution sales and earnings. The quarter ends October 3; that is not a scheduled earnings release. No new company event has been verified inside September 28–October 2. The case is continuation of a disclosed operating upcycle, contingent on price behaviour and the October 1 manufacturing reading.
What the price confirms—and what it does not. The $100.91 close was above SMA20 $93.57 and SMA50 $91.89, with the intermediate average up 2.57% over ten sessions. August 24–September 24 price performance was +16.98%, versus IWM −5.47%. September 24 IBKR volume was 1.65× normal. These are stronger momentum observations than a stock merely bouncing below falling averages. The cost of that strength is extension: the close was 7.84%, or about 1.94 ATR, above SMA20. A favourable narrative may already be substantially reflected in the price.
What would strengthen the case. A stable consolidation that absorbs the recent advance, or a close above the observed $102.70 twenty-session high with sustained participation, would add evidence. A large opening gap without follow-through would not. The operational question remains whether growing shipments turn into cash as inventories and receivables normalize. No assumption is made about quarter-end fund flows or compulsory institutional buying.
What would weaken or invalidate the case. A rapid loss of the recent range and then the $93.57–91.89 average area would weaken momentum; the $90.90 ten-session low is the structure’s lower observed reference. The financial caveat is material: fiscal 2026 operating cash flow was negative $280.9 million, while June 27 debt was $3.213 billion against $155.4 million cash. A $650 million convertible creates potential dilution above its conversion economics. The August $550 million note financing was intended for refinancing; it cannot simply be added to June debt as a net increase. The 10-K also disclosed a $375 million variable-rate term loan entered into in August, maturing in July 2028. The June debt balance is therefore not a current pro-forma debt total. This is a leveraged distributor benefiting from stronger demand, not a cash-rich defensive semiconductor proxy.
August 5 results and outlook · Fiscal 2026 Form 10-K · August 21 financing filing
Observed reference range: prior-20-session high $102.70; latest 10-session low $90.90. ATR14 $3.79 (3.75% of the close). These describe the chart, not an entry, stop order or price objective. No company event on September 28–October 2 is assumed unless explicitly listed.
Blue: SMA20. Purple: SMA50 (starts only when 50 observations are available). Candles: green close ≥ open; red close < open. Lower bars: IBKR reported volume, scaled to the chart maximum. No future prices or projected returns. On small screens, scroll the chart horizontally.
Source: IBKR daily RTH TRADES; Merlintrader calculations. Prices through September 24, 2026.
Fresh news earns attention, but it does not erase a damaged intermediate trend or a weak response to the announcement. These two names are conditional research cases and carry a higher uncertainty label.
Conditional event case: Fresh earnings and a QNX design win, with unusually strong volume but an unrepaired intermediate trend
September 24 close $8.73 · SMA20 $8.00 · SMA50 $8.34 · volume/prior20 3.88× (IBKR series)
Business evidence and why now. BlackBerry supplied two specific developments: on September 22, Coretura became the first QNX/Vector Alloy Kore design win, representing more than $100 million of royalty backlog; on September 24, fiscal Q2 revenue reached $163.3 million, up 26%, including 27% QNX growth. Management raised fiscal 2027 revenue guidance to $616–636 million and expected operating cash flow of approximately $115 million. The royalty backlog is future business, not immediate revenue. The next week’s question is whether investors continue to absorb these newly disclosed operating facts after the initial earnings reaction.
What the price confirms—and what it does not. The September 24 close of $8.73 was near the day’s $8.80 high after a $7.93 low. The stock gained 9.26% from September 18 and closed above both averages. Relative volume was 3.88× in the IBKR series and 3.87× using Finviz history: the demand signal is supported by both vendors. Nevertheless, SMA50 had fallen 7.05% over ten sessions and the stock was already 9.12% above SMA20. A strong one-day response is not the same as a repaired intermediate trend.
What would strengthen the case. Holding the post-results $7.93–8.80 range and then establishing closes above $8.80, followed by the earlier $9.22 high, would strengthen the continuation interpretation. Failure to retain the earnings reaction would make the headline less useful. These levels describe what would need to be observed; no automatic follow-through from an earnings beat is assumed, and no unverified consensus estimate is used.
What would weaken or invalidate the case. A sustained return below the $8.34–8.00 averages, or a loss of the $7.93 earnings-session low, would undermine the immediate event thesis. The longer ten-session low is $7.46. Licensing contributed $22.1 million in Q2, versus about $6 million guided for Q3; next-quarter revenue guidance of $143–154 million is below Q2. Secure communications dollar-based net retention was 91%. At August 31, cash and investments of $447.1 million included $14.1 million restricted cash, alongside $197.1 million of notes. A lumpy licensing quarter and equity dilution remain relevant despite the stronger QNX narrative.
September 22 Coretura filing · September 24 issuer results · Fiscal Q2 Form 10-Q
Observed reference range: prior-20-session high $9.22; latest 10-session low $7.46. ATR14 $0.45 (5.17% of the close). These describe the chart, not an entry, stop order or price objective. No company event on September 28–October 2 is assumed unless explicitly listed.
Blue: SMA20. Purple: SMA50 (starts only when 50 observations are available). Candles: green close ≥ open; red close < open. Lower bars: IBKR reported volume, scaled to the chart maximum. No future prices or projected returns. On small screens, scroll the chart horizontally.
Source: IBKR daily RTH TRADES; Merlintrader calculations. Prices through September 24, 2026.
Conditional event case: A new federal contract extension with an orderly chart, but no confirmed improvement in bookings
September 24 close $32.43 · SMA20 $32.08 · SMA50 $29.47 · volume/prior20 0.80× (IBKR series)
Business evidence and why now. On September 24, Everforth ECS announced a three-year sole-source SUNet IDIQ extension with a $148 million ceiling and a separate selection to research and prototype SUNet 2.0. IDIQ means indefinite delivery/indefinite quantity: the ceiling is not a guaranteed order, revenue or cash receipt. This specific award is supported by one issuer announcement; it has not been independently validated against a government award record in this edition. It is still a real, dated company development rather than an assumed benefit from general defence spending.
What the price confirms—and what it does not. The September 24 close of $32.43 was above SMA20 $32.08 and SMA50 $29.47; SMA50 had risen 11.40% over ten sessions. The price was only 1.08% above the short average. That is a less extended chart than BB or AVT. However, the stock lost 1.01% from September 18 and volume was only 0.80× its IBKR prior-20-session norm. It therefore fails the positive-week filter used for the three technical candidates and remains explicitly conditional. The contract announcement has not yet generated a confirmed new price impulse.
What would strengthen the case. Continued acceptance above $32.08, followed by a stronger close through the observed $34.42 high with expanding participation, would link the new contract story to actual market demand. A quiet stock after an announcement is not automatically an undiscovered opportunity. Funded orders, task-order timing and improvement in federal book-to-bill would provide stronger business confirmation than repeating the ceiling value.
What would weaken or invalidate the case. A sustained loss of SMA20 would weaken the near-term structure; the observed $30.24 low is the more demanding warning, with SMA50 below it. July 29 Q2 revenue was $1.007 billion versus $1.021 billion a year earlier, and adjusted EBITDA declined to $96.7 million from $108.5 million. Federal book-to-bill for the trailing twelve months ended June 30 was 0.8, so the new award does not yet prove a broad order recovery. The business also carries substantial debt. Its July refinancing was described as leverage-neutral, not deleveraging. Federal budget timing, contract execution, task-order funding and weaker commercial demand can offset the attractive headline.
September 24 SUNet announcement · July 29 Q2 results · July refinancing
Observed reference range: prior-20-session high $34.42; latest 10-session low $30.24. ATR14 $1.72 (5.31% of the close). These describe the chart, not an entry, stop order or price objective. No company event on September 28–October 2 is assumed unless explicitly listed.
Blue: SMA20. Purple: SMA50 (starts only when 50 observations are available). Candles: green close ≥ open; red close < open. Lower bars: IBKR reported volume, scaled to the chart maximum. No future prices or projected returns. On small screens, scroll the chart horizontally.
Source: IBKR daily RTH TRADES; Merlintrader calculations. Prices through September 24, 2026.
All times are U.S. Eastern Daylight Time. Rome is six hours ahead during this week. Announced dates remain subject to change. September 30 is also quarter-end; any claim about compulsory buying or “window dressing” would require positioning evidence that is not available here.
| Date | Confirmed event | How it connects to the research |
|---|---|---|
| Mon Sep 28 · 13:00 ET | FSM at Mining Forum Americas. Issuer schedule. | A confirmed presentation, not a promised operating update. FSM remains outside the main selection because its short-term chart is weak. |
| Tue Sep 29 · 10:00 ET | August JOLTS. BLS calendar. | Labour demand can change the market’s rate expectations. No directional assumption is assigned to the number. |
| Tue Sep 29 · after close | AIR fiscal Q1 results; call 17:00 ET. AAR schedule. CNXC fiscal Q3 results. Concentrix schedule. | AIR is still below both averages. CNXC is close to SMA20 with a rising SMA50. Earnings gaps can override either structure; the date alone is not a positive signal. |
| Wed Sep 30 · 08:30 ET | Q2 GDP third estimate and August Personal Income and Outlays, including PCE. BEA schedule. | Inflation and demand matter across all five cases, particularly valuation-sensitive technology shares. These releases occur together. |
| Wed Sep 30 · after close | PRGS fiscal Q3 results; call 17:00 ET. Company schedule. | The September 22 closing of the $400 million Domo AI/data acquisition makes funding, integration and updated outlook concrete questions. PRGS remains below both averages. Acquisition closing. |
| Thu Oct 1 · 10:00 ET | September ISM Manufacturing PMI. ISM calendar. | Relevant to AVT’s electronics cycle and wider industrial risk appetite; a strong survey is not guaranteed to lift the shares. |
| Fri Oct 2 · 08:30 ET | September Employment Situation. BLS calendar. | Payrolls, unemployment and wages can alter both rate and growth expectations. This is the final major macro test of the selected week. |
AIR, PRGS and CNXC appear because their results are scheduled; they are not added to the main technical selection. A favourable surprise is possible, but a reporting date alone does not establish the direction or size of the gap.
All five previous technical setups were down from September 18 to September 24. Their simple equal-weight average price change was −5.90%, versus −0.86% for IWM, a shortfall of 5.04 percentage points. This is a partial-week research audit, not the return of an implemented portfolio. It excludes September 25, dividends, costs and any actual trade execution.
The prior table’s “Week” column described September 11–18, before the September 19 publication. It was historical context, not the subsequent outcome. The audit below explicitly separates those dates. It preserves every prior name instead of retaining only the winners.
| Ticker | Prior editorial group | Sep 18 close | Sep 24 close | Price change |
|---|---|---|---|---|
| KBH | Calendar / forward preview | 47.12 | 47.65 | +1.12% |
| THO | Calendar / forward preview | 67.77 | 70.93 | +4.66% |
| MLKN | Calendar / forward preview | 20.66 | 19.91 | -3.63% |
| WOR | Calendar / forward preview | 57.38 | 60.33 | +5.14% |
| WS | Calendar / forward preview | 33.33 | 35.48 | +6.45% |
| CRL | Calendar / forward preview | 278.06 | 294.44 | +5.89% |
| AIR | Calendar / forward preview | 112.77 | 120.56 | +6.91% |
| FSM | Technical selection | 11.95 | 11.50 | -3.77% |
| EXK | Technical selection | 10.21 | 9.16 | -10.28% |
| HBM | Technical selection | 26.90 | 26.48 | -1.56% |
| STNG | Technical selection | 87.16 | 80.96 | -7.11% |
| TNK | Technical selection | 100.92 | 94.08 | -6.78% |
| AVAV | Additional comparisons | 159.95 | 158.55 | -0.88% |
| HYLN | Additional comparisons | 4.20 | 4.20 | +0.00% |
| AEHR | Additional comparisons | 93.49 | 97.42 | +4.20% |
| BKSY | Additional comparisons | 21.67 | 23.17 | +6.92% |
| PL | Additional comparisons | 16.42 | 17.62 | +7.31% |
Across all 17 previous cases, nine rose, seven fell and one was unchanged. That mixed result does not rescue the specifically positive technical selection: its five names all declined. Three miners and two tanker companies concentrated the selection in two linked risk clusters. Three miners also lacked a completed short-term recovery; the tankers were already extended. This edition gives technical confirmation and concentration a stricter role.
The failed cases remain relevant to the method. A close below an observed reference can signal that the original structure has weakened, but it is not proof an investor could have exited at that price. Gaps, spreads and overnight news make such an assumption unreliable.
| Candidate | What attracted attention | Reason for exclusion or lower priority |
|---|---|---|
| EXK | Silver exposure and last week’s rebound thesis. | September 22 issuer notice: Guanacevi’s primary mill stopped September 21; repairs expected to take about three weeks, with throughput about 600 versus 1,100 tonnes/day. Close $9.16 is below both averages. Operational update. |
| FSM / STNG / TNK | Precious metals, freight rates and previously rising intermediate trends. | All are below SMA20 at the cutoff. They need a new recovery signal; a conference or favourable sector narrative does not repair the failed short-term selection. No automatic rollover. |
| FSLY | Investor Day and +11.82% since September 18. | The September 24 session lost 10.02%, on 2.61× IBKR relative volume. ATR14 is about 10% of price. The positive multi-day number masks a sharp reversal; this is not a clean momentum lead. |
| WTTR | September 24 agreement to acquire Pilot Water for $700 million, before contingent consideration. | Consideration includes $600 million cash and $100 million stock, adding financing and dilution risk. At September 24 close $19.53, the stock was below both averages; the September 25 call and premarket response are outside the chart cutoff. Closing is expected in Q4, not guaranteed next week. Acquisition filing. |
| NNBR | Raised guidance and recent price recovery. | Below the $300 million and $5 screening thresholds at the discovery snapshot. September 30 shareholders vote on doubling authorized common shares from 90 million to 180 million. Authorization is not automatic issuance, but financing complexity makes it unsuitable for the main list. Proxy. |
| POWL / AMSC / PLAB | Electrical infrastructure or semiconductor-cycle exposure. | All were still below SMA50 at the completed-session cutoff. POWL and AMSC also had falling intermediate averages. Interesting businesses remain watch items until their charts repair. |
| QLYS | Cash-rich cybersecurity business, raised guidance and a rising SMA50. | A credible reserve, but September 24 closed near the session low after reaching $190, with only 0.48× IBKR volume. It needs stabilization rather than an assumed breakout. Its financial quality is stronger than AVT’s leverage profile; technical evidence does not erase that trade-off. August 4 results. |
| EFXT | Gas-infrastructure orders, lower leverage and positive one-month relative strength. | Near the $23.28 prior high, but the September 24 close did not hold the intraday breakout, SMA50 was still drifting down and U.S.-line liquidity was thinner than most developed cases. A reserve, not a forced fifth technical name. Q2 results. |
| GAP | Improving technical position and an increased adjusted EPS outlook. | Q2 sales fell 2% and comparable sales 1%. Reported gross margin included an 11.4-percentage-point net benefit from expected tariff recoveries; that is not recurring operating improvement. Q2 results. |
| HBM / CRDO / LITE | Copper or AI-infrastructure interest. | Above the declared $10 billion research ceiling at the screening snapshot. A familiar ticker does not qualify as a mid cap merely because it appeared in earlier coverage. |
Geopolitical tension is not a universal positive catalyst. Refining margins, tanker freight and producer cash flow depend on different variables, while a demand shock or normalization of shipping routes can hurt several exposures together. The new list is therefore not another concentrated bet on a single commodity or shipping narrative.
All displayed closes, chart candles and technical calculations use IBKR daily regular-session TRADES observations through September 24, 2026. The retained extracts contain 83 sessions per instrument. SMA20 and SMA50 are arithmetic means of the most recent 20 and 50 closes; the intermediate slope compares SMA50 with its value ten sessions earlier. The chart shows 60 sessions, with a moving-average curve only where sufficient prior observations exist.
Price change = (ending close / starting close − 1) × 100. The audit and short comparison use September 18–24; the longer comparison uses August 24–September 24. Relative strength in the summary is the stock’s return minus IWM’s return, in percentage points. These are price returns, not reinvested-dividend returns. A positive relative result can coexist with an absolute loss.
Volume ratio = September 24 volume divided by the average of the preceding 20 sessions, excluding September 24. It is calculated entirely within the IBKR series. Finviz historical checks agree with IBKR on all 126 closing prices checked across six names and 21 matched dates, but reported volumes differ. SPNT’s relative-volume magnitude differs materially; the above-normal direction agrees. No claim of consolidated exchange volume is made. Provider quantities are not mixed in one ratio.
The prior20 high excludes the latest session; the 10-session low includes it. ATR14 uses Wilder smoothing of true ranges from the four-month extract and is an estimate of recent price variability, not a loss limit. Small high/low differences between data vendors may alter an exact pivot by a few cents. Charts and levels contain no projected prices.
Capitalization classification uses a $300 million–$10 billion research band, with market screening checked against the latest dated common-share count where disclosed. The market values below are Merlintrader calculations using September 24 prices and those earlier share counts, not real-time fully diluted valuations. Repurchases, stock compensation, convertibles and later issuance can change the share base.
| Ticker | Published common shares and date | Indicative equity value at Sep 24 close | Primary share-count source |
|---|---|---|---|
| SPNT | 116,165,016 · July 24, 2026 | $2.997bn | Form 10-Q cover |
| SPSC | 36,000,174 · July 23, 2026 | $2.977bn | Form 10-Q cover |
| AVT | 82,072,979 · August 7, 2026 | $8.282bn | Form 10-K cover |
| BB | 587,032,279 · September 21, 2026 | $5.125bn | Form 10-Q cover |
| EFOR | 41.0 million (issuer-rounded) · July 24, 2026 | about $1.330bn | Form 10-Q cover |
The aim is to improve selection quality, not to promise profitable outcomes. Three technical candidates and two conditional event cases replace an undifferentiated long list. A headline, conference appearance, analyst mention or rebound after a large loss is not sufficient on its own.
U.S.-listed common equities, non-biotech remit and an indicative $300 million–$10 billion market value. The initial Finviz discovery filters used price above $5, average daily volume above 500,000 shares, positive weekly performance and price above SMA20 and SMA50. That live snapshot can include premarket prices, so every developed setup was recalculated at the same completed-session cutoff. Names added through primary-source news still need the same security and risk checks.
Operating results, cash conversion, contract economics, financing and the precise timing of news. An IDIQ ceiling is not guaranteed revenue; a buyback authorization is not a completed purchase; a product launch is not an order. If a conference or reporting date is the only new fact, the name remains in the calendar rather than becoming a bullish selection.
Relative strength, position above the averages, direction of the intermediate trend, volume and the latest candle are assessed together. A positive weekly percentage can hide heavy selling in the most recent session. A breakout needs a close and subsequent acceptance, not just an intraday touch. An already stretched move receives a lower priority even if the business story is attractive.
Every case carries both a price-based warning and a business risk. The cases can remain unconfirmed or fail entirely. An absent setup is preferable to filling a quota. This is an editorial watchlist, with no allocations, entry instructions, price targets or measured success probabilities.
No assumption of undiscovered value is made. The good news may already be reflected in the price. There is no complete options-implied move, analyst-consensus model or positioning study in this edition, so it does not claim a quantified valuation advantage, a short squeeze or a probability of outperformance.
Government awards, commercial wins, product launches, regulatory decisions and strategic milestones that can change what the market expects, each with the document that establishes it.
Revenue quality, margins, backlog conversion, guidance and the distance between what management said it would deliver and what it delivered.
Cash, runway, debt, share issuance, warrants, convertibles and the at-the-market programmes that quietly reshape per-share value.
Liquidity, valuation, concentration, ownership, insider activity and the specific events that would invalidate the prevailing narrative.
Company facts retain their original reporting periods and announcement dates. Market data were retrieved September 25, with September 24 as the latest completed-session cutoff. Material information released later on September 25 or over the weekend may change the analysis. No automatic follow-up or ongoing monitoring is implied.
Related research: Weekly Market Pulse, Insider Trading Weekly and Free Biotech Catalyst Calendar.
Join the Merlintrader Telegram channel for the weekly list, market recaps and research updates the moment they are published.
Join @merlintraderpub_com on TelegramEducational research only. This page is published for educational and informational purposes. It is not investment advice, not a recommendation, and not an offer or solicitation to buy or sell any security. Merlintrader is not a registered investment adviser or broker-dealer. Small and mid-cap securities can be highly volatile and may have limited liquidity. Company filings, market data and scheduled dates can be revised by the issuer or the agency that published them, and past performance does not indicate future results. Always do your own research and consult a licensed financial adviser before making any investment decision. Full disclaimer: merlintrader.com/disclaimer.
